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Summary
Objective: To examine the expression pattern of human cartilage glycoprotein 39 (HC gp-39) mRNA in human cartilage and bone.
Design: In-situ hybridization analysis was used to examine the expression pattern of human cartilage glycoprotein 39 (HC gp-39) mRNA in
adult human osteoarthritic articular cartilage from various stages of disease, as well as in human osteophytic tissue and in human fetal bone.
Results: In cartilage from patients with mild osteoarthritic cartilage degeneration, HC gp-39 was expressed at moderate to high levels only
in chondrocytes of the superficial zone. In advanced OA cartilage, cloning chondrocytes of the superficial zone expressed high levels of HC
gp-39 and chondrocytes of the mid- and deep zones were also positive. HC gp-39 was undetectable in the chondrocytes of normal articular
cartilage. In osteophytic tissue, the expression of HC gp-39 mRNA was intense in flattened, end-stage osteoblasts and in primary osteocytes
in both endochondral and intramembranous bone formation. Proliferating osteoblasts expressed low to moderate levels. Notably, mature
osteocytes were negative for HC gp-39 expression. Chondrocytes in the secondary ossification center of developing fetal cartilage
demonstrated high expression while growth plate and mineralized cartilage chondrocytes had lower expression. Osteoblasts at sites of
endochondral and intramembranous bone formation were positive for expression of HC gp-39.
Conclusions: The stage-specific expression of HC gp-39 in fetal development and adult remodelling bone and cartilage provides evidence
for a specific functional or structural role for HC gp-39 in bone and cartilage tissue. HC gp-39 is expressed in diseased human osteoarthritic
cartilage and osteophyte, but not in non-diseased tissue, and its distribution within the tissue changes as disease progresses. OA is
characterized not only by cartilage degeneration, but by increased subchondral bone formation and osteophytosis. The results from this
study indicate that the increased HC gp-39 expression in OA serum and synovial fluid may reflect not only cartilage degeneration but
increased osteogenesis. © 2000 OsteoArthritis Research Society International
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Human cartilage glycoprotein 39 (HC gp-39) is a member
of the mammalian protein family related in sequence to the
bacterial chitinases.1 It is also referred to as YKL-40 based
on the one-letter code for its first three N-terminal amino
acids and its apparent molecular mass of 40 kDa.2 HC
gp-39 has been reported as a major secretory glycoprotein
of cultured human articular chondrocytes and synovial
fibroblasts.1 Although HC gp-39 mRNA (by Northern analy-
sis) and protein (by Western analysis) were undetectable
in normal cartilage, HC gp-39 was reported to be highly
expressed in rheumatoid (RA) cartilage and synovium.1
Additionally, increased levels of protein are detected in the
serum and synovial fluid of patients with osteoarthritis (OA)
and RA.3–4 It is also secreted by the human osteoblast cell
line, MG63,2 in response to 1,25-(OH)2D3 treatment (along
with alkaline phosphatase and osteocalcin; late osteoblast
differentiation markers), or extended time in culture. In87contrast, HC gp-39 has not been detected in normal
primary osteoblasts isolated from fetal and adult human
bone under equivalent conditions.2
The expression of HC gp-39 has been detected in
tissues in which there is a high level of tissue remodelling.
Initially, it was reported in whey protein secretions concur-
rent with the involution of the bovine mammary gland
following cessation of lactation.5 Additionally, in human
tissues, it has been described as a secreted protein in
cultured synovial cells6 and articular chondrocytes;1,7 as
a marker in metastatic breast cancer;8 and in liver.1,9
Kirkpatrick et al.10 have reported the in-situ expression of
HC gp-39 mRNA in inflammatory macrophages of human
rheumatoid synovium.
Although the protein contains regions of homology with a
group of bacterial and fungal chitinases, glycosidic activity
against chitinase substrates has never been demon-
strated.1 Recently, Renkema et al.11 have shown that HC
gp-39 is a chitin-binding lectin, however, its true physiologi-
cal role remains unclear.
Currently, there are no data to identify the specific cell
types responsible for the in-vivo expression of HC gp-39 in
rheumatoid or osteoarthritic cartilage. In this report, we
describe the in-situ expression of HC gp-39 mRNA in fetal
and adult human cartilage and osteoarthritic osteophytes.
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TISSUE PROCESSING
Osteophytes from osteoarthritic femoral heads were
obtained with informed consent from patients undergoing
joint replacement surgery for osteoarthritis from the
Rothman Institute (Philadelphia, PA). The osteophytes
were dipped in a 5% solution (w/v) of polyvinyl alcohol and
then chilled (−70°C) by precipitate immersion in cooled
n-hexane. Adult articular cartilage and fetal bone obtained
from the Anatomical Gift Foundation (Laurel, MD) were
collected in under 6 h post mortem and snap-frozen prior to
shipment. Ten samples of adult articular cartilage from
eight different patients (42–93 years of age) and including
femoral head, femoral condyl and tibial plateau were ana-
lyzed. Four normal, six early OA and four advanced OA
sites within the tissue samples were studied. Two samples
of fetal bone (ulna, 10 and 11 weeks gestational age) were
analyzed. Cryostat sections (5 m) of unfixed, undecalci-
fied bone were cut on a modified Hacker cryostat equipped
with a finely polished tungsten-tipped steel knife and
collected onto 3-aminopropyltriethoxy silane coated slides.
The disease state of the adult articular cartilage was
characterized by the following criteria: (a) normal cartilage
had a smooth, intact superficial zone and no indication of
proteoglycan loss (as determined by toluidine blue staining)
from the mid- or deep zones; (b) early OA damage included
slight fissuring of the superficial zone and loss of proteo-
glycan from the zones immediately surrounding the
chondrocytes in the mid- and deep zones; (c) advanced OA
cartilage included deep and extensive fissuring of the
superficial zone with characteristic cloning of chondrocytes
and extensive proteoglycan loss throughout the mid- and
deep zones.HISTOLOGICAL STAINING
Serial sections were stained with a modified aqueous
Romanowsky Wright stain (fast green in methanol, eosin G
and methylene blue/azure A; Baxter Scientific). Sections
were fixed for 30 sec in fast green/methanol and dipped
directly into the eosin for 30 sec. Sections were then
stained directly with methylene blue/azure A for 1 min and
washed in distilled water, air dried and mounted in DPX
mountant (BDH Laboratory Supplies, Poole, England).ALKALINE PHOSPHATASE ACTIVITY
To aid in the identification of osteoblast populations,
alkaline phosphatase activity was assayed in unfixed,
undecalcified sections, at pH 9.2 by the simultaneous
naphthol phosphate method, with Fast Red TR as the
coupler. The reaction buffer (0.2 mg/ml naphthol AS-MX
phosphate in 2% N,N dimethylformamide, 0.1 M TrisHCl,
1 mg/ml Fast Red TR salt) was prepared and filtered
immediately before staining. The sections were incubated
for 3 min at room temperature in the reaction buffer. A red
precipitate denotes sites of alkaline phosphatase activity.
The sections were mounted in 90% glycerol and 10% PBS.RNA PROBE
pBluescript SK containing the coding region of human
HC gp-39 was obtained from Human Genome Sciences(Rockville, MD). cDNA template was linearized with XhoI,
then transcribed from the T3 promoter to generate the
sense strand (negative control) or with XbaI, then tran-
scribed from the T7 promoter to generate the antisense
(positive) strand. Riboprobes were prepared using the
Promega (Madison, WI) In Vitro transcription kit with 35S-
thio CTP (Amersham, Arlington Heights, IL). Following
transcription, cDNA templates were digested with RQ1
RNAse-free DNAse I (Promega, Madison, WI), and un-
incorporated nucleotides were removed by centrifugation
through Quick Spin Sephadex G-50 columns (Boehringer-
Mannheim, Indianapolis, IN). RNA transcripts with a
specific activity in excess of 108 cpm/mg were used for
hybridization.IN-SITU HYBRIDIZATION
In-situ hybridization was performed by the original
method of Zeller and Rogers12 with modifications detailed
by Dodds et al.,13 as follows. Cryosections were fixed in
4% paraformaldehyde, washed, dehydrated and frozen at
−20°C. Prior to hybridization, sections were hydrated,
demineralization and acetylated. Hybridization was carried
out at 42°C for 4 h and post-hybridization washes were to a
final stringency of 0.1×SSC (20×SSC: 3 M NaCl, 0.3 M Na
citrate, pH 7.0). Sections were dehydrated, air dried and
coated in Amersham LM-1 emulsion. Following exposure at
4°C for 2 weeks, the slides were developed in Kodak
developer and counterstained with methylene blue. The
extent of the hybridization signal was assessed by the
autoradiographic grain density over the cell and was scored
in a range from +/− through + + + + corresponding to
just over background levels through intense levels of
expression.ResultsEXPRESSION OF HC GP-39 MRNA IN CHONDROCYTES OF NORMAL
HUMAN ARTICULAR CARTILAGE
There was negligible expression of HC gp-39 mRNA in
chondrocytes in non-diseased human articular cartilage
(Fig. 1A–C). This cartilage was characterized by a smooth,
intact superficial zone and with no indication of proteo-
glycan loss from the mid- or deep-zones. Four normal
sites were analyzed (data shown from a representative
individual).EXPRESSION OF HC GP-39 MRNA IN CHONDROCYTES FROM EARLY
AND ADVANCED OSTEOARTHRITIC HUMAN ARTICULAR CARTILAGE
Articular cartilage with early osteoarthritic damage was
characterized by slight fissuring of the superficial zone and
in loss of proteoglycan from the zones immediately sur-
rounding the chondrocytes in the mid- and deep zones (Fig.
1D–F). The HC gp-39 mRNA expression in the chondro-
cytes from this early stage of disease was confined primar-
ily to the superficial zone and there was a range in the level
of expression (+ + to + + + +) (Fig. 1D and E).
Tissue damage in advanced osteoarthritic cartilage
included deep and extensive fissuring of the superficial
zone with characteristic cloning of chondrocytes and exten-
sive proteoglycan loss throughout the mid- and deep zones
(Fig. 2A–F). In advanced osteoarthritic cartilage, HC gp-39
mRNA expression was detectable in the chondrocytes of
Osteoarthritis and Cartilage Vol. 8 No. 2 89Fig. 1. Expression of HC gp-39 mRNA in chondrocytes of normal and early osteoarthritic human articular cartilage. Cryostat sections were
hybridized with the HC gp-39 antisense (A–E) or sense (F) strand riboprobe and counterstained with methylene blue. (A) Normal human
articular cartilage from the tibial plateau of a 71-year-old. HC gp-39 mRNA was not detected in the superficial, mid-or deep zones of normal
cartilage. Magnification ×10. (B) High power view of the superficial zone of (A). Magnification ×20. (C) High power view of the deep zone
of (A) showing individual chondrocytes (arrows) and consistent staining of the matrix proteoglycans surrounding the chondroctyes
(arrowhead). Magnification ×40. (D) Early OA human articular cartilage from the femoral head of a 73-year-old with mild fissuring and loss
of matrix proteoglycans in the mid- and deep zones. Magnification ×10. (E) High power view of the superficial zone of (D). Intense expression
of HC gp-39 mRNA was observed in chondrocytes of the superficial zone (arrows). Moderate levels of expression were demonstrated
in the mid-zone chondrocytes (arrowheads). Magnification ×40. (F) Serial section of (E) hybridized with the HC gp-39 sense control.
Magnification ×40.the remaining, mid- and deep zones (Fig. 2A–C). The
cloning chondrocytes associated with the deep fissuring of
the superficial zone had moderate to high (+ + to + + +)
levels of HC gp-39 mRNA (Fig. 2C, D). In less damaged OA
cartilage, a range of expression was observed (+/− to + +)with the highest level in the mid-zone and the lowest in the
deep zone. In contrast, as the disease progresses more
intense expression of HC gp-39 was seen in the deep zone
cells (Fig. 2E, F). Overall, the expression of HC gp-39
mRNA increased with the extent of tissue damage.
90 J. R. Connor et al.: Human cartilage glycoprotein 39 (HC gp-39)Fig. 2. Expression of HC gp-39 mRNA in chondrocytes of advanced osteoarthritic human articular cartilage. Cryostat sections were
hybridized with the HC gp-39 antisense (A-F) riboprobe and counterstained with methylene blue. (A) Deeply fissured OA cartilage from the
femoral condyl of a 93-year-old demonstrating high levels of HC gp-39 mRNA expression in the chondrocytes (arrows) of the mid-zone (m)
and low levels of expression in the deep zone (d) chondrocytes (arrowheads). Magnification ×10. (B) Higher magnification of the mid-zone
of (A) demonstrating high expression of HC gp-39 mRNA. Magnification ×20. (C) Advanced OA cartilage with deep fissuring demonstrating
high levels of HC gp-39 mRNA expression in cloning chondrocyte clusters (arrowheads) of the mid-zone (m) and moderate expression in the
deep zone chondrocytes (arrows). Magnification ×10. (D) Higher magnification of cloning chondrocyte clusters in (C) with high HC gp-39
mRNA expression. Magnification ×20. (E) Advanced OA cartilage with loss of the superficial zone. Cloning chondrocytes in the mid-zone (m)
demonstrated moderate HC gp-39 expression (arrowheads) and chondroctyes of the deep zone (d) showed higher expression of HC gp-39
compared to (A) and (C) above. Magnification ×10. (F) Higher magnification of the deep zone of (E) demonstrating higher levels of HC gp-39
mRNA expression in these chondrocytes with the progression of the disease. Magnification ×20.DEVELOPING HUMAN OSTEOPHYTIC TISSUE
A cross-section of undecalcified, human osteophytic
tissue stained for alkaline phosphatase activity is shown inFig. 3. Sites of intramembranous and endochondral
bone formation are present within the fibrocartilaginous
covering.
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HC gp-39 mRNA expression was detected in osteoblasts
at sites of intramembranous and endochondral ossification
within developing osteophyte (Fig. 4). A pattern of matur-
ation stage-dependent expression of HC gp-39 in human
osteoblasts was observed in forming trabeculae at sites of
endochondral bone formation where the most intense
expression of HC gp-39 mRNA was found in end-stage
osteoblasts and in primary osteocytes (Fig. 4A–C). In
contrast, HC gp-39 expression was low to moderate in
osteoid-forming and proliferating osteoblasts (Fig. 4C).
During intramembranous bone formation, endstage osteo-
blasts also demonstrated intense HC gp-39 expression at a
level comparable to primary osteocytes (Fig. 4D–G). The
gradation of HC gp-39 mRNA from moderate (in alkaline-
phosphatase positive proliferating osteoblasts) to high levels
(in end-stage osteoblasts) was observed in several of the
samples.
Serial sections reacted for alkaline phosphatase activity
and HC gp-39 mRNA expression at sites of intramembra-
nous bone formation (Fig. 4H and I) show intense expres-
sion in endstage osteoblasts and primary osteocytes.
However, HC gp-39 was undetectable in fully encased,
mature osteocytes and reduced in flattened lining cells (Fig.
4F and I).EXPRESSION OF HC GP-39 MRNA IN HUMAN FETAL CARTILAGE
In developing fetal cartilage (Fig. 5A, C, D), chondro-
cytes expressed high levels of HC gp-39 mRNA in the
pre-secondary ossification center and high to moderate
levels in the cartilage growth plate. The sense strand,
negative control (Fig. 5B) showed no background hybrid-
ization signal. In areas of mineralized cartilage, however,the expression was reduced (Fig. 5A). Osteoblasts at sites
of intramembranous bone formation on the outer rudiment
core expressed moderate levels of HC gp-39; osteoblasts
involved in endochondral bone formation expressed high
levels of HC gp-39 (Fig. 5C). Low levels of expression were
detected in articular chondrocytes (Fig. 5D).Fig. 3. A developing human osteophyte. An undecalcified cryostat cross-section of a developing human osteophyte reacted for alkaline
phosphatase (red) activity. The mineralized bone appears as dark brown (e.g., white *). The fibrocartilage covering (fib) and cartilage growth
plate (cart) are indicated. Sites intramembranous bone formation (arrowheads) where osteoid (black *) is being layed down and sites of
endochondral bone formation (arrows) are shown. Magnification ×5.Discussion
HC gp-39 is expressed in both the articular chondrocytes
of OA cartilage and osteoblasts in osteophytic tissue at
sites of active repair or turnover. Normal chondrocytes and
fully embedded, mature osteocytes did not express detect-
able levels of HC gp-39. These data are consistent with the
recent report of Volck et al.14 who demonstrated, by im-
munohistochemical analysis, the expression of HC gp-39
protein in the superficial and middle zones of osteoarthritic
cartilage from the femoral head. They reported low HC
gp-39 protein staining in normal cartilage. Our data are
consistent also with joint fluid and serum data which
indicated that HC gp-39 levels in serum and synovial fluid
correlate positively with joint disease severity. Harvey et
al.4 have developed an ELISA assay for the analysis of HC
gp-39 protein in human serum. They have demonstrated
significantly greater HC gp-39 levels in serum from patients
with active RA and OA patients, compared to normal,
inactive RA or diabetes patients. Additionally, clinical
improvement in samples from patients treated with
antirheumatic drug therapy corresponded with decreased
HC gp-39 values. They concluded that HC gp-39 may be a
useful marker of arthritis. Johansen et al.3 also reported
that synovial fluid and serum levels of HC gp-39 correlated
significantly with indices of joint disease in patients with
inflammatory and degenerative joint disease. In patients
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Osteoarthritis and Cartilage Vol. 8 No. 2 93Fig. 5. HC gp-39 mRNA expression in human fetal cartilage. Cryostat sections were hybridized with the HC gp-39 antisense riboprobe and
counterstained with methylene blue. (A) Low power view demonstrating HC gp-39 mRNA expression in zones of developing fetal cartilage
(ulna, 10 weeks gestation age). High expression was detected in the chondrocytes of the pre-secondary ossification center (2nd OC). The
cartilage growth plate (CGP) chondrocytes had moderate levels of expression and expression was reduced in mineralized cartilage (MC).
Magnification ×5. (B) Serial section of (A) hybridized with the sense strand riboprobe. Magnification ×5. (C) High magnification view of
mineralized cartilage (MC) and areas of endochondral bone formation (arrows) showing high levels of HC gp-39 in osteoblasts. Osteoblasts
(*) involved in intramembranous bone formation had significant levels of HC gp-39. Magnification ×20. (D) Articular cartilage chondrocytes
(arrowheads) expressed low to moderate levels of HC gp-39 mRNA. Magnification ×20.Fig. 4. HC gp-39 mRNA expression at sites of intramembranous and endochondral bone formation in the developing human osteophyte.
(A–I) High magnification of Fig. 3. (A) A cryostat section hybridized with the HC gp-39 antisense riboprobe shows intense expression in
endstage osteoblasts (arrows) and primary osteocytes (arrowheads) at sites of endochondral bone formation. Magnification ×10. (B) Higher
magnification serial section of (A) stained with Wright stain. End stage osteoblasts (arrow) and primary osteocytes (arrowheads) are
indicated. Magnification ×100. (C) Higher magnification of (A) hybridized with the HC gp-39 antisense riboprobe. Intense mRNA expression
was observed in endstage osteoblasts (large and small arrows) and primary osteocytes (arrowheads) at sites of endochondral bone
formation. Osteoid forming and proliferating osteoblasts demonstrated low to moderate expression. Magnification ×100. (D) Histology
showing osteophytic intramembranous bone formation with areas of osteoblast proliferation (OPg) and primary osteocytes. The thick osteoid
(o) seam is indicated. Magnification ×50. (E) Serial section reacted for alkaline phosphatase activity demonstrating late stage osteoblasts
(arrow) and primary osteocytes (arrowhead). Magnification ×50. (F) Serial section hybridized with the HC gp-39 antisense riboprobe. Newly
formed osteocytes (primary osteocytes; arrowhead) demonstrate intense HC gp-39 mRNA expression. The fully encased osteocytes were
negative (small arrows). Proliferating and end stage osteoblasts demonstrate significant expression patterns (large arrow). Magnification
×50. (G) Serial section of (F) hybridized with the sense strand riboprobe. Magnification ×50. (H) Section reacted for alkaline phosphatase
activity in intramembranous bone formation. Alkaline phosphatase positive late stage osteoblasts (arrow), primary osteocytes (large
arrowhead) and lining cells (small arrowheads) are shown. Magnification ×50. (I) Serial section of (H) hybridized with the HC gp-39 antisense
probe. Intense expression was observed in endstage osteoblasts (arrow) and primary osteocytes (large arrowheads), but low expression
was observed in lining cells. Magnification ×50.with early rheumatoid arthritis (disease duration <3 years),
Johansen et al.15 have shown that persistently elevated
serum HC gp-39 levels correlated positively with risk of
radiological disease progression as determined by Larsen
score.
The in-situ hybridization data in this study indicate that
the HC gp-39 mRNA levels increased with disease progres-
sion. This was apparent not only in the articular cartilagebut also in the bone formation and remodelling associated
with the osteophyte. In diseased osteophytic tissue, the
highest level of HC gp-39 mRNA expression was detected
in late stage osteoblasts which were forming osteoid and in
primary osteocytes. HC gp-39 mRNA was not detected in
osteoclasts (data not shown). Additionally, the HC gp-39
mRNA was undetectable in mature osteocytes encased in
mineral. These high levels of expression suggest that these
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seen in OA patients. Although not analyzed in this study,
the possibility exists that the subchondral bone thickening
often associated with osteoarthritis, also contributes to the
increased level of HC gp-39 protein in the serum and
synovial fluid of patients.
Reports of maturation-stage dependent and induced
expression of HC gp-39 in various cell types have been
published by several groups.2,10,16 HC gp-39 mRNA
expression was shown in PMA-induced morpho-
logical differentiation of monocytes into macrophages by
Kirkpatrick10 and in differentiating macrophages by Rehli.16
In cultured osteoblastic MG-63 cells, Johansen2 demon-
strated HC gp-39 protein in culture supernatants induced
by extended culture of confluent cultures or by treatment
with 1,25-(OH)2D3. The induction of HC gp-39 protein was
not observed in 7 day cultures of normal adult or fetal
primary osteoblasts. This observation is in agreement with
our data that mature osteoid forming osteoblasts express
HC gp-39.
While HC gp-39 belongs structurally to the glycosyl
hydrolase family 18, it had been previously reported by
Watanabe et al.17 that the chitinase activity of the mole-
cules were dependent on a glutamic acid residue and an
aspartic acid residue (Glu204 and Asp200). The absence of
the Glu204 in HC gp-39 was believed to account for its lack
of enzyme activity. Working with human activated macro-
phages which secrete HC gp-39 and chitotriosidase and
using site directed mutagenesis, Renkema et al.11 have
recently demonstrated that a single amino acid substitution
in the catalytic domain of the chitotriosidase resulted in a
similar sequence to HC gp-39, the loss of hydrolytic activity
and the capacity to bind to chitin. They postulate that the
chitin binding activity of HC gp-39 expressed by human
macrophages may be a mechanism by which macro-
phages exert their anti-fungal properties. Chitin is a struc-
tural component in the cell walls of fungi and it is exposed
during hyphal growth. HC gp-39 binding of chitin could
act by preventing chitin remodelling during hyphal growth.
Chitins are a large family of glycans composed of 1,4-
linked, linear polymers of 2-deoxy-2-acetamido-D-glucose
(N-acetyl glucosamine). Chitin is similar in composition
to hyaluronic acid, a linear polysaccaride, composed
disaccharides of -1,4-D-glucuronate--1,3-N-acetyl glu-
cosamine.18 Hyaluronic acid is a major component of
cartilage with multiple physiological roles including lubri-
cation of the joint, maintenance of the water content in
tissue, regulation of the transport of molecules in the
extracelluar space and the exclusion and partitioning of
macromolecules and proteins in tissue compartments.18
Increasing numbers of proteins which bind specifically to
hyaluronic acid are being discovered.19 In cartilage, for
example, multiple link proteins are bound to individual
hyaluronic acid molecules and may play a role in stable
aggregation of aggrecan with hyaluronic acid. The binding
of these proteins to hyaluronic acid may confer altered
functional characteristics to the resulting complex. If HC
gp-39 binds to hyaluronic acid, it may change the functional
properties of the molecule. Additionally, its location in the
pericellular zone suggests a role for hyaluronic acid in
regulation of cell activities.18
The primary osteocytes and OA cartilage chondrocytes
which express high levels of HC gp-39 mRNA have very
similar structural and functional characteristics in their
respective tissue types and they are derived from the same
multipotent mesenchymal stem cell. Both osteocytes and
chondrocytes are encased in specialized matrices whichenable them to function as mechanosensory cells in bone
and cartilage, respectively. The osteocytes may modify the
matrix directly surrounding them to allow for the diffusion of
nutrients, oxygen and waste products through the lacuno-
canalicular system. Production and secretion of specific
matrix molecules may be important for the osteocytes
capacity to regulate their own adhesion and, thereby their
sensitivity to mechanical stress signals.20 Similar in many
aspects to osteocytes in bone, articular cartilage chondro-
cytes are surrounded by a pericellular matrix rich in proteo-
glycans containing a significant proportion of the total
cartilage matrix hyaluronic acid.21 The high level of HC
gp-39 mRNA expression in osteoarthritic cartilage chondro-
cytes (clusters) and in late stage osteoblasts and primary
osteocytes suggests a role for this molecule in the structure
of the specialized matrix surrounding these cells which may
include the binding of HC gp-39 to hyaluronic acid.
Many studies have demonstrated marked changes in the
structural, biochemical and metabolic profile of the
chondrocyte and its pericellular microenvironment in both
spontaneous and experimentally induced OA. The evi-
dence for the active role of the chondrocyte in the control
and progression of OA suggests that pericellular matrix
remodelling is important in the etiology of osteoarthritic
degeneration. Poole et al.22 have suggested that the initial
changes in the collagen and proteoglycan distribution
within the chondron are followed by chondrocyte prolifer-
ation to form clusters. Associated with these morphological
changes are redistribution and reorganization of the com-
ponents of the chondron. The appearance of chondrocyte
clusters in OA cartilage and of hypertrophic cells has
suggested that the continued stimulation of chondrocytes in
OA might eventually lead to chondrocyte hypertrophy, and
thus to enhanced type X collagen synthesis.23,24 Type X
collagen has been identified in the matrix of OA cartilage at
sites of deep fibrillation, in chondrocyte clusters and in the
deeper zones of OA cartilage.25 In human fetal growth
plate, hypertrophic chondrocytes are positive for type X
collagen expression;23 therefore it has been proposed that
the progression of OA disease mimics stages of normal
fetal cartilage development.25 In a similar pattern as type X
collagen expression, HC gp-39 mRNA was expressed in
both the chondrocyte clusters in adult OA cartilage and in
the hypertrophic chondrocytes of developing fetal cartilage.
This provides additional support for the idea that HC gp-39
expression and function are related to a stage specific cell
event such as the formation of the chondron in fetal
development and the restructuring of the pericellular matrix
surrounding the chondrocyte in adult OA cartilage.
Osteoarthritis is characterized not only by cartilage
degradation, but by increased subchondral bone formation
and osteophytosis. The results from this study indicate that
the increased HC gp-39 protein levels detected in the
serum and synovial fluid of OA patients may reflect
increased osteogenesis associated with osteophytosis in
addition to cartilage breakdown. Additionally, the pattern of
expression in fetal development and adult remodelling
bone and cartilage suggests a structural role for HC gp-39
in bone and cartilage tissue.Acknowledgments
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